Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The anticancer drug ellipticine activated with cytochrome P450 mediates DNA damage determining its pharmacological efficiencies: studies with rats, Hepatic Cytochrome P450 Reductase Null (HRN™) mice and pure enzymes

M. Stiborová, V. Černá, M. Moserová, I. Mrízová, VM. Arlt, E. Frei,

. 2015 ; 16 (1) : 284-306. [pub] 20141225

Language English Country Switzerland

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

Ellipticine is a DNA-damaging agent acting as a prodrug whose pharmacological efficiencies and genotoxic side effects are dictated by activation with cytochrome P450 (CYP). Over the last decade we have gained extensive experience in using pure enzymes and various animal models that helped to identify CYPs metabolizing ellipticine. In this review we focus on comparison between the in vitro and in vivo studies and show a necessity of both approaches to obtain valid information on CYP enzymes contributing to ellipticine metabolism. Discrepancies were found between the CYP enzymes activating ellipticine to 13-hydroxy- and 12-hydroxyellipticine generating covalent DNA adducts and those detoxifying this drug to 9-hydroxy- and 7-hydroellipticine in vitro and in vivo. In vivo, formation of ellipticine-DNA adducts is dependent not only on expression levels of CYP3A, catalyzing ellipticine activation in vitro, but also on those of CYP1A that oxidize ellipticine in vitro mainly to the detoxification products. The finding showing that cytochrome b5 alters the ratio of ellipticine metabolites generated by CYP1A1/2 and 3A4 explained this paradox. Whereas the detoxification of ellipticine by CYP1A and 3A is either decreased or not changed by cytochrome b5, activation leading to ellipticine-DNA adducts increased considerably. We show that (I) the pharmacological effects of ellipticine mediated by covalent ellipticine-derived DNA adducts are dictated by expression levels of CYP1A, 3A and cytochrome b5, and its own potency to induce these enzymes in tumor tissues, (II) animal models, where levels of CYPs are either knocked out or induced are appropriate to identify CYPs metabolizing ellipticine in vivo, and (III) extrapolation from in vitro data to the situation in vivo is not always possible, confirming the need for these animal models.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15031540
003      
CZ-PrNML
005      
20171215201515.0
007      
ta
008      
151005s2015 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms16010284 $2 doi
035    __
$a (PubMed)25547492
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Stiborová, Marie $u Department of Biochemistry, Faculty of Science, Charles University, Hlavova 2030, CZ-12843 Prague 2, Czech Republic. stiborov@natur.cuni.cz.
245    14
$a The anticancer drug ellipticine activated with cytochrome P450 mediates DNA damage determining its pharmacological efficiencies: studies with rats, Hepatic Cytochrome P450 Reductase Null (HRN™) mice and pure enzymes / $c M. Stiborová, V. Černá, M. Moserová, I. Mrízová, VM. Arlt, E. Frei,
520    9_
$a Ellipticine is a DNA-damaging agent acting as a prodrug whose pharmacological efficiencies and genotoxic side effects are dictated by activation with cytochrome P450 (CYP). Over the last decade we have gained extensive experience in using pure enzymes and various animal models that helped to identify CYPs metabolizing ellipticine. In this review we focus on comparison between the in vitro and in vivo studies and show a necessity of both approaches to obtain valid information on CYP enzymes contributing to ellipticine metabolism. Discrepancies were found between the CYP enzymes activating ellipticine to 13-hydroxy- and 12-hydroxyellipticine generating covalent DNA adducts and those detoxifying this drug to 9-hydroxy- and 7-hydroellipticine in vitro and in vivo. In vivo, formation of ellipticine-DNA adducts is dependent not only on expression levels of CYP3A, catalyzing ellipticine activation in vitro, but also on those of CYP1A that oxidize ellipticine in vitro mainly to the detoxification products. The finding showing that cytochrome b5 alters the ratio of ellipticine metabolites generated by CYP1A1/2 and 3A4 explained this paradox. Whereas the detoxification of ellipticine by CYP1A and 3A is either decreased or not changed by cytochrome b5, activation leading to ellipticine-DNA adducts increased considerably. We show that (I) the pharmacological effects of ellipticine mediated by covalent ellipticine-derived DNA adducts are dictated by expression levels of CYP1A, 3A and cytochrome b5, and its own potency to induce these enzymes in tumor tissues, (II) animal models, where levels of CYPs are either knocked out or induced are appropriate to identify CYPs metabolizing ellipticine in vivo, and (III) extrapolation from in vitro data to the situation in vivo is not always possible, confirming the need for these animal models.
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové látky $x farmakologie $7 D000970
650    _2
$a cytochrom P-450 CYP1A1 $x nedostatek $x genetika $x metabolismus $7 D019363
650    12
$a poškození DNA $7 D004249
650    _2
$a elipticiny $x farmakologie $7 D004611
650    _2
$a hepatocyty $x účinky léků $x metabolismus $7 D022781
650    _2
$a myši $7 D051379
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a rozpřahující látky $x farmakologie $7 D014475
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Černá, Věra $u Department of Biochemistry, Faculty of Science, Charles University, Hlavova 2030, CZ-12843 Prague 2, Czech Republic. vera.cerna@natur.cuni.cz.
700    1_
$a Moserová, Michaela $u Department of Biochemistry, Faculty of Science, Charles University, Hlavova 2030, CZ-12843 Prague 2, Czech Republic. michaela.moserova@natur.cuni.cz.
700    1_
$a Mrízová, Iveta $u Department of Biochemistry, Faculty of Science, Charles University, Hlavova 2030, CZ-12843 Prague 2, Czech Republic. iveta.vranova@natur.cuni.cz.
700    1_
$a Arlt, Volker M. $u Analytical and Environmental Sciences Division, MRC-PHE Centre for Environmental & Health, King's College London, 150 Stamford Street, London SE1 9NH, UK. volker.arlt@kcl.ac.uk. $7 xx0074763 $4
700    1_
$a Frei, Eva $u Division of Preventive Oncology, National Center for Tumor Diseases, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. eva.frei@t-online.de.
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 16, č. 1 (2015), s. 284-306
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25547492 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20151005 $b ABA008
991    __
$a 20151013104113 $b ABA008
999    __
$a ok $b bmc $g 1092416 $s 914666
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 16 $c 1 $d 284-306 $e 20141225 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
LZP    __
$a Pubmed-20151005

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...